Overview

Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study will test the safety and efficacy of intra-arterial chemotherapy in subjects with newly diagnosed, residual, or recurrent atypical choroid plexus papilloma and choroid plexus carcinoma prior to a second surgery. It is believed that intra-arterial chemotherapy will be safe and feasible for this population and will result in decreased tumor size, which may further improve the goals of a second-look surgery.

Phase:

Phase 1

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Columbia University

Treatments:

Carboplatin
Melphalan
Topotecan